Bristol Myers drug combo fails to meet main goal in kidney cancer trial | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  10070 of 10756  at  7/29/2022 8:20:50 AM  by

al monte


Bristol Myers drug combo fails to meet main goal in kidney cancer trial

 
 

July 29 (Reuters) - Bristol Myers Squibb (BMY.N) said on Friday a trial evaluating a combination of its two cancer drugs failed to meet the primary goal to treat localized kidney cancer.

The combination of the two drugs - Yervoy and top selling cancer drug Opdivo - is already approved in the United States as a first line of treatment for patients with renal cell carcinoma that has spread.

However, the combination failed to meet the key endpoint of disease-free survival for patients who had localized form of the cancer and had undergone full or partial removal of the kidney.



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 3  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...